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Evidence-Based Medicine (EBM) is characterized 
by integrating individual clinical expertise with 
the best available external clinical evidence from 
systematic research (David Sackett). But the large 
amount of available biomedical literature gives 
healthcare practitioners much difficulty in 
locating the best evidence regarding each clinical 
question.
Non-steroidal anti-inflammatory drugs (NSAID) have been widely used 
in various diseases as rheumatoid arthritis, cancers and  also served as 
painkillers. It includes the most commonly used Aspirin and  the recent 
controversial drugs Vioxx and Bextra. We studied the evolution of 
NSAID research from 1990-2005.
In this study we combined information 
visualization techniques with bibliographic tools 
like co-citation analysis and co-keyword analysis to 
automatically extract the best external evidence out 
of the vast body of medical literature.
In order to better track and represent the best 
evidences, we combined the biomedical literature 
database Medline and the citation database Web of 
Science together. 
Here is our framework, it can be also extended to 
incorporate more data sources. 
Background Case Study Results
Conclusion
Our Approach
We used CiteSpace – a java application designed for 
knowledge domain visualization to visualize cluster 
views and time zone views. 
CiteSpace website:  
http://cluster.cis.drexel.edu/~cchen/citespace/
Cluster view of the evolution of NSAID and the 
top-5 most frequently found MeSH terms
Cluster: Adverse Effects of Traditional, Non-selective Inhibitors
160: Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
42: Gastrointestinal Hemorrhage/*chemically induced
36: Aspirin/*adverse effects
28: Gastrointestinal Diseases/*chemically induced
26: Peptic Ulcer/*chemically induced
24: Helicobacter pylori 
Cluster: Adverse Effects of Selective Inhibitors
46: Anti-Inflammatory Agents, Non-steroidal/*adverse effects
34: Cyclooxygenase Inhibitors/*therapeutic use
34: Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
24: Cyclooxygenase Inhibitors/*pharmacology 
22: Isoenzymes/*antagonists & inhibitors
Cluster: Cyclooxygenase
28: Anti-Inflammatory Agents, Non-steroidal/*pharmacology
26: Cyclooxygenase Inhibitors/*pharmacology
12: Prostaglandin-Endoperoxide Synthase/*genetics; metabolism
8: Aspirin/*pharmacology; Prostaglandins/*biosynthesis; 
Thiazines/*pharmacology; Thiazoles/*pharmacology 
Cluster: Colonic Neoplasms 
22: Anti-Inflammatory Agents, Non-steroidal/*pharmacology
22: Colonic Neoplasms/* prevention &control  
18: Apoptosis/*drug effects
16: Aspirin/*therapeutic use
14: Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
These five clusters perfectly match the main applications and recent research 
fronts of NASID described in several  meta-analysis papers, which are the 
gold standards we used to evaluate our results. 
Time zone view of NSAID
The success of NSAID case study proved the feasibility 
of our approach. This trail will lead us to the future 
design of visualization-based evidence searching tools 
for EBM. 
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(1991) prostaglandin-synthesis
(1994) h-2-receptor-antagonists
(1999) pump-inhibitors
(2000) selective-cox-2-inhibitor
(2003) S-disease (Alzheimer’s)
(2004) pump-inhibitors
•The first peak of pump-
inhibitors is corresponding 
to the beginning of COX 
research. It aimed to reduce 
the side effects of NSAID. 
The main products are 
Vioxx and Bextra
•The second peak referred 
to the withdrawal of Vioxx 
in 2004 by Merck & Co, 
which incurred people 
switching to previous 
NSAID research. 
http://www.fda.gov/cder/drug/infopage/
COX2/default.htm
Cluster: Alzheimer disease
14: Anti-Inflammatory Agents, Non-steroidal /therapeutic use
10: Alzheimer Disease/*epidemiology
8: Alzheimer Disease/*prevention &Control
8:Alzheimer Disease/*drug therapy
6:Alzhzimer Disease/*pathology 
